



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/647,841	10/05/2000	Ilga Winicov	5475-US	4329

7590 06/18/2002
Richard R. Mybeck
Post Office Box 5540
Scottsdale, AZ 85261-5540

EXAMINER

BAUM, STUART F

ART UNIT PAPER NUMBER

1638

DATE MAILED: 06/18/2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

09/647841

EXAMINER

Stuart Baum

ART UNIT	PAPER
----------	-------

1638

9

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

The communication filed May 3, 2002 is not fully responsive to the Office communication mailed 22 April, 2002 for the reason(s) set forth on the attached Notice To Comply With The Sequence Rules or CRF Diskette Problem Report. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the reply appears to be bona fide attempt to comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825), applicant is given a TIME PERIOD of ONE (1) MONTH from the mailing date of this communication within which to correct the deficiency so as to comply with the sequence rules (37 CFR 1.821 - 1.825) in order to avoid abandonment of the application under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Examiner Stuart Baum, Art Unit 1638, whose telephone number is (703) 305-6997.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

ELIZABETH F. McELWAIN
PRIMARY EXAMINER
GROUP 1800

E. F. McElwain

Notic to Comply	Application N . <i>09/647841</i>	Applicant(s)	
	Examiner Stuart Baum	Art Unit 1638	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: *Raw Sequence listing report*

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200.

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Art Unit: 1638

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS Submission
User Manual - ePAVE)

2. Mailed to:
U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:
U. S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at:
2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
Arlington, Virginia 22202

1638
Please
consult
sequence rules.
Reply
Not Needed

TIME: 08:49:03

Does it comply

Corrected Discrepancy Needed

activation Please see
sample sequence
Listing (attached)
Does Not Comply for valid
Corrected Diskette Needed format.

↑
use this
date format

use lower-case
/ letters when
sequence listing

is in "new" sequence
Rule format

numbers
off

1) Per 1.822 of
sequence
rules,
group all
non-coding bases
into 10's, with
a space between
each group of 10.

RAW SEQUENCE LISTING

DATE: 06/03/2002

PATENT APPLICATION: US/09/647,841A

TIME: 08:49:03

Input Set : A:\PTO.VSK.txt

Output Set: N:\CRF3\06032002\I647841A.raw

E--> 40 tcacacccaattctcttaagtgtatgacttcatagtacactacactactttctttgaaac

E--> 41 atggctaactatgctctagccaatgttttcaccttctcttgaacttgagtaccttactc

1

60

All sample Sequence Listing (attached)

<110> Smith, John; Smithgene Inc.
 <120> Example of a Sequence Listing
 <130> 01-00001
 <140> PCT/EP98/00001
 <141> 1998-12-31
 <150> US 08/999,999
 <151> 1997-10-15
 <160> 4
 <170> PatentIn version 2.0
 <210> 1
 <211> 389
 <212> DNA
 <213> Paramecium sp.
 <220>
 <221> CDS
 <222> (279)...(389)
 <300>
 <301> Doc. Richard
 <302> Isolation and Characterization of a Gene Encoding a
 Protease from Paramecium sp.
 <303> Journal of Genes
 <304> 1
 <305> 4
 <306> 1-7
 <307> 1988-06-31
 <308> 123456
 <309> 1988-06-31
 <400> 1
 agctgtagtc attcctgtgt cctcttctct ctgggcttct caccctgcta atcagatctc 60
 agggagagtg tcttgacctt cctctgcctt tgcagcttca caggcaggca ggcaggcagc 120
 tgaatgtggca attgctggca gtgccacagg ctttccagcc aggccttaggg tgggttcgcg 180
 cgcggcgcgg cggccctctt cgcgctcttc tcgcgctctt ctctcgctct cctctcgctc 240

Please consult

Appendix 3, page 2

ggacctgatt aggtgagcag gaggaggggg cagtttagc atg gtt tca atg ttc agc 296
Met Val Ser Met Phe Ser
1 5

ttg	tct	ttc	aaa	tgg	cct	gga	ttt	tgt	ttg	ttt	gtt	tgt	ttg	ttc	caa	344
Leu	Ser	Phe	Lys	Trp	Pro	Gly	Phe	Cys	Leu	Phe	Val	Cys	Leu	Phe	Gln	
			10					15					20			

tgt	ccc	aaa	gtc	ctc	ccc	tgt	cac	tca	tca	ctg	cag	ccg	aat	ctt			
Cys	Pro	Lys	Val	Leu	Pro	Cys	His	Ser	Ser	Leu	Gln	Pro	Asn	Leu			389
		25					30					35					

<210>	2
<211>	37
<212>	PRT
<213>	Paramecium sp.

<400> 2
Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu
1 5 10 15

Phe Val Cys Leu Phe Gln Cys Pro Lys Val Leu Pro Cys His Ser Ser
20 25 30

Leu Cln Pro Asn I.eu
35.

<210>	3
<211>	11
<212>	PORT
<213>	Artificial Sequence

<220>	
<221>	Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

Met Val Asn Leu Glu Pro Met His Thr Glu Ile
1 5 10

<210>	4
<400>	4
000	

[Annex VIII follows]